Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: A population-based cohort study

British Journal of Haematology

Volumn 165, Issue 4, 2014, Pages 489-496

  Wieringa, Andre ^a,b   Boslooper, Karin ^c   Hoogendoorn, Mels ^d   Joosten, Peter ^d   Beerden, Tim ^a   Storm, Huib ^d   Kibbelaar, Robby E ^b   Veldhuis, Gerrit J ^e   Van Kamp, Harmen ^f   Van Rees, Bastiaan ^g   Kluin Nelemans, Hanneke C ^c   Veeger, Nic J G M ^h   Van Roon, Eric N ^a,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Department of Clinical Pharmacy Isala Klinieken ^*  (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d MEDICAL CENTER LEEUWARDEN   (Netherlands)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f NIJ SMELLINGHE HOSPITAL   (Netherlands)

^g Tjongerschans Hospital   (Netherlands)

^h Department of Epidemiology MCL Academy   (Netherlands)

Author keywords

Comorbidity; Diffuse large B cell lymphoma; Population based; R CHOP; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; DEMENTIA; DIABETES MELLITUS; DISEASE COURSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART INFARCTION; HEMIPLEGIA; HUMAN; INFECTION; KIDNEY DISEASE; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER DISEASE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PERIPHERAL VASCULAR DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SOLID TUMOR; TREATMENT OUTCOME; ULCER; VENOUS THROMBOEMBOLISM; VERY ELDERLY;

COMORBIDITY; DIFFUSE LARGE B-CELL LYMPHOMA; POPULATION-BASED; R-CHOP; TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOVASCULAR DISEASES; COMORBIDITY; CYCLOPHOSPHAMIDE; DIABETES MELLITUS; DOXORUBICIN; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; INFECTION; KIDNEY DISEASES; LIVER DISEASES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NETHERLANDS; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84899479606     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12765     Document Type: Article

References (28)

1. Aapro, M.S., Bohlius, J., Cameron, D.A., Dal Lago, L., Donnelly, J.P., Kearney, N., Lyman, G.H., Pettengell, R., Tjan-Heijnen, V.C., Walewski, J., Weber, D.C. & Zielinski, C. & European Organisation for Research and Treatment of Cancer. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer, 47, 8-32.
2. Birim, O., Kappetein, A.P. & Bogers, A.J. (2005) Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. European Journal of Cardio-Thoracic Surgery, 28, 759-762.
3. Boslooper, K., Kibbelaar, R., Storm, H., Veeger, N.J., Hovenga, S., Woolthuis, G., van Rees, B., de Graaf, E., van Roon, E., Kluin-Nelemans, H.C., Joosten, P. & Hoogendoorn, M. (2013) Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leukemia & Lymphoma, doi:10.3109/10428194.2013.810737.
4. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases, 40, 373-383.
5. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. & International Harmonization Project on Lymphoma. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
6. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346, 235-242.
7. Cunningham, D., Hawkes, E.A., Jack, A., Qian, W., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K.M., Radford, J.A., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J. & Linch, D. (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet, 381, 1817-1826.
8. Extermann, M., Overcash, J., Lyman, G.H., Parr, J. & Balducci, L. (1998) Comorbidity and functional status are independent in older cancer patients. Journal of Clinical Oncology, 16, 1582-1587.
9. Firat, S., Byhardt, R.W. & Gore, E. (2002) Comorbidity and karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. radiation therapy oncology group. International Journal of Radiation Oncology, Biology, Physics, 54, 357-364.
10. Guzzo, T.J., Dluzniewski, P., Orosco, R., Platz, E.A., Partin, A.W. & Han, M. (2010) Prediction of mortality after radical prostatectomy by charlson comorbidity index. Urology, 76, 553-557.
11. Hoogendoorn, M., Joosten, P., Storm, H. & Kibbelaar, R.E. (2009) HemoBase: Een intelligent elektronisch patiëntendossier als coach voor de hemato-oncologische zorg. Nederlands Tijdschrift Voor Hematologie, 6, 104-110.
12. Janssen-Heijnen, M.L., Houterman, S., Lemmens, V.E., Louwman, M.W., Maas, H.A. & Coebergh, J.W. (2005a) Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Critical Reviews in oncology/hematology, 55, 231-240.
13. Janssen-Heijnen, M.L., van Spronsen, D.J., Lemmens, V.E., Houterman, S., Verheij, K.D. & Coebergh, J.W. (2005b) A population-based study of severity of comorbidity among patients with non-hodgkin's lymphoma: prognostic impact independent of international prognostic index. British Journal of Haematology, 129, 597-606.
14. Kobayashi, Y., Miura, K., Hojo, A., Hatta, Y., Tanaka, T., Kurita, D., Iriyama, N., Kobayashi, S. & Takeuchi, J. (2011) Charlson comorbidity index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 137, 1079-1084.
15. Lee, L., Crump, M., Khor, S., Hoch, J.S., Luo, J., Bremner, K., Krahn, M. & Hodgson, D.C. (2012) Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. British Journal of Haematology, 158, 481-488.
16. Li, X., Liu, Z., Cao, J., Hong, X., Wang, J., Chen, F., Wang, C., Zou, S., Li, J. & Shen, Z. (2012) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in china: a 10-year retrospective follow-up analysis of 437 cases from shanghai lymphoma research group. Annals of Hematology, 91, 837-845.
17. Lugtenburg, P., Silvestre, A.S., Rossi, F.G., Noens, L., Krall, W., Bendall, K., Szabo, Z. & Jaeger, U. (2012) Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clinical Lymphoma, Myeloma & Leukemia, 12, 297-305.
18. National Cancer Institute. Common terminology criteria for adverse events. 2006.
19. Ouellette, J.R., Small, D.G. & Termuhlen, P.M. (2004) Evaluation of charlson-age comorbidity index as predictor of morbidity and mortality in patients with colorectal carcinoma. Journal of Gastrointestinal Surgery, 8, 1061-1067.
20. Piccirillo, J.F., Tierney, R.M., Costas, I., Grove, L. & Spitznagel, E.L. Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. Journal of the American Medical Association, 291, 2441-2447.
21. Read, W.L., Tierney, R.M., Page, N.C., Costas, I., Govindan, R., Spitznagel, E.L. & Piccirillo, J.F. (2004) Differential prognostic impact of comorbidity. Journal of Clinical Oncology, 22, 3099-3103.
22. Sehn, L.H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J.J., Sutherland, J., Wilson, K.S., Gascoyne, R.D. & Connors, J.M. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in british columbia. Journal of Clinical Oncology, 23, 5027-5033.
23. Seki, R., Ohshima, K., Nagafuji, K., Fujisaki, T., Uike, N., Kawano, F., Gondo, H., Makino, S., Eto, T., Moriuchi, Y., Taguchi, F., Kamimura, T., Tsuda, H., Ogawa, R., Shimoda, K., Yamashita, K., Suzuki, K., Suzushima, H., Tsukazaki, K., Higuchi, M., Utsunomiya, A., Iwahashi, M., Imamura, Y., Tamura, K., Suzumiya, J., Yoshida, M., Abe, Y., Matsumoto, T. & Okamura, T. (2010) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in japan: a retrospective analysis of 1, 057 cases from kyushu lymphoma study group. International Journal of Hematology, 91, 258-266.
24. Singh, B., Bhaya, M., Stern, J., Roland, J.T., Zimbler, M., Rosenfeld, R.M., Har-El, G. & Lucente, F.E. (1997) Validation of the charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. The Laryngoscope, 107, 1469-1475.
25. van Spronsen, D.J., Janssen-Heijnen, M.L., Breed, W.P. & Coebergh, J.W. (1999) Prevalence of co-morbidity and its relationship to treatment among unselected patients with hodgkin's disease and non-hodgkin's lymphoma, 1993-1996. Annals of Hematology, 78, 315-319.
26. van Spronsen, D.J., Janssen-Heijnen, M.L., Lemmens, V.E., Peters, W.G. & Coebergh, J.W. (2005) Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based eindhoven cancer registry. European Journal of Cancer, 41, 1051-1057.
27. Swerdlow, S.H., Campoo, E. & Harris, N.L. (2008) WHO Classification of Tumours of Haematopoietic and Lymfoid Tissues. IARC, Lyon, France.
28. Wildes, T.M., Augustin, K.M., Sempek, D., Zhang, Q.J., Vij, R., Dipersio, J.F. & Devine, S.M. (2008) Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 14, 840-846.